Object. In this study, long-term results are presented from clinical studies of the Bryan Cervical Disc Prosthesis at University Hospital Gasthuisberg in Leuven, Belgium. A total of 98 patients (89 with 1-level and 9 with 2-level implantations) agreed to participate in follow-up studies for up to 10 years postoperatively. This article focuses on the 4-and 6-year results. Patients in one of the clinical studies had either radiculopathy or myelopathy associated with spondylosis and/or disc herniations that did not respond to conservative treatment. Patients from the other clinical study received commercially available Bryan devices and the study protocol did not have specific inclusion/exclusion criteria. More than 90% of the patients were considered to have radiculopathy.
T he inclusion of patients for the first prospective multicenter trial using the Bryan Cervical Disc Prosthesis (Medtronic) for the treatment of patients with single and bilevel degenerative disc disease of the cervical spine was initiated in Europe on January 5, 2000, and was concluded in April 2001. The clinical 1-and 2-year results of this trial have been published and were satisfactory in comparison with short-and intermediate-term clinical outcomes associated with ACDF reported in the literature. 5, 7 Since 2002, Bryan discs have been implanted worldwide and have been the subject of clinical studies; the 1-and 2-year results of these studies have also been published. 1, 4, 8, 12, 13, [17] [18] [19] In the US a prospective, randomized, multicenter FDA Investigational Device Exemption study has been performed comparing Bryan discs with ACDF using allografts in combination with plating. 2, 3, 14, 15 The 2-year results in this study were satisfactory for the Bryan discs: both cervical disc replacement and ACDF showed a low incidence of significant adverse events related to the procedure. 2 Although both surgical groups demonstrated statistically significant improvement in all clinical outcome measures with respect to their preoperative scores, the outcome-based group-to-group comparison at the follow-up intervals was highly suggestive of the benefit of the investigational implant; 15 almost twice as many reoperations, both at the index and adjacent levels, occurred in the control compared with the arthroplasty group. 2 However, the follow-up period for all studies published to date has been limited to 2 years or less, and in each publication it was concluded that a follow-up period longer than 2 years would be needed to assess the real clinical benefit of artificial disc technology. 3, 5, 7, 8, 12, 14, 15, 17, 18 
Methods

Study Population
This article reports longer-term outcomes (up to 6 years after surgery) of patients who received the Bryan disc at University Hospital Gasthuisberg in Leuven, Belgium. The patient population for these evaluations arose from 2 clinical studies. The first study, Phase I, was a clinical study sponsored by Medtronic that examined 1-and 2-level implantations of the device at 7 investigational centers located in Europe. 5, 7 One of the investigational centers was University Hospital Gasthuisberg where 54 patients in the 146-patient cohort were enrolled (44 with 1-level and 10 with 2-level implantations). The first 1-level surgery was performed on January 5, 2000, and the last procedure occurred on April 19, 2001 . The surgery dates for 2-level procedures were from June 12, 2001 , to April 16, 2002 . This study focused on patient outcomes up to 2 years postoperatively.
An additional 48 patients were enrolled in a second study, Phase II, at University Hospital Gasthuisberg. All of these patients underwent 1-level implantations. The first surgery in the Phase II study was performed on May 31, 2001, and the last on October 18, 2002 . This study required follow-up visits beyond 2 years, extending out to 10 years postoperatively. In addition, patients from the earlier Phase I study were asked to become participants in the Phase II study and be evaluated beginning 4 years postoperatively. Both the Phase I and Phase II studies were executed according to protocols that were reviewed and approved by the local ethics committee. Patient informed consent was required for both studies. In addition, the Phase I study patients who participated in the extended follow-up in the Phase II study were asked to sign an informed consent addendum.
Patients who received the Bryan device in both studies had either radiculopathy or myelopathy associated with spondylosis and/or disc herniations that did not respond to conservative treatment. The Phase I protocol dictated specific inclusion/exclusion criteria ( Table 1 ). The Phase II study used commercially available Bryan devices and did not have protocol-specified inclusion/exclusion criteria. All operations were performed using the classic firstgeneration set of instruments. 5, 7 Outcome Assessment
There was considerable overlap in the patient assessment methodology in both the Phase I and Phase II studies. Patient demographic information and preoperative status were recorded. Surgery-related data such as operative time, blood loss, and level/levels treated were collected.
Investigators performed a neurological examination similarly on patients in both the Phase I and Phase II studies. Motor, sensory, and reflex assessments were made. The results from each parameter were summarized as a percent of maximum (normal) for the measurements of each parameter. If the postoperative percentage score was no worse than the preoperative score for each pa- rameter (sensory, motor, and reflexes), the neurological outcome was considered a success. Good outcomes in all 3 parameters were necessary to be considered an overall neurological success at each postoperative time period.
Patients were instructed to complete the SF-36 10 at the various study periods in both the Phase I and Phase II studies. The results are presented as the PCS and the MCS for this article. There were a few differences in patient assessments between the 2 studies. The Phase II study asked patients to complete an NDI 16 questionnaire at each visit. This is also true for the extended follow-up patients from the Phase I study. The Phase I study protocol required the use of the Cervical Spine Research Society patient questionnaire, not the NDI. Therefore, long-term result comparisons to preoperative status cannot be made for Phase I study patients. Also, patients in the Phase II study were asked to grade the amount of neck and arm pain at each visit. Numeric rating scales were used, 9 which ranged from 0 (none) to 10 (unbearable). Such measurements were not obtained in the Phase I study.
In addition, the general outcomes for each patient in the 2 studies were graded based on the Odom classification. 11 However, the methods differed for the 2 studies. The Odom classification for the Phase I study was based on an algorithm that included results from the Cervical Spine Research Society questionnaire and the neurological assessment as reported by Goffin et al. 5 However, in the Phase II study, a general Odom classification question was posed to the investigator. Regardless, the Odom classification categorizes the patient's outcome from "excellent" to "poor" and represents the degree of preoperative symptom relief and impairment improvement following surgery.
Radiographs were obtained at each postoperative visit to assess the range of motion. Angular motion was based on Cobb angle measurements on lateral flexion-extension radiographs. All radiographic measurements were performed by an independent board-certified radiologist. Device safety was monitored at each visit in both studies. Adverse events and surgical procedures after the Bryan device implantation were recorded and evaluated.
Statistical Analysis
The Fisher exact test was used to analyze categorical data and continuous data were compared with an ANOVA. Statistical significance was considered if the p value was < 0.05. A Kaplan-Meier life table was constructed for a time-to-event analysis.
Results
Study Enrollment and Demographics
The total potential patient population for long-term follow-up was 98 patients: 89 underwent 1-level placement and 9 underwent 2-level placement ( Table 2 ). The Phase I study originally had 44 1-level patients and 10 2-level patients. However, only 41 1-level and 9 2-level patients chose to participate in the extended follow-up study. A total of 48 1-level patients were enrolled in the Phase II 
* Preoperative weight and height were missing in 2 and 6 patients, respectively.
study. At the time of the last patient follow-up visit, all 89 1-level and 9 2-level patients were beyond 4 postoperative years. Furthermore, 53 patients who underwent 1-level procedures and 6 patients who underwent 2-level procedures were at least 6 years postoperative at that time. The 1-level patients from the Phase I and Phase II studies were demographically similar, and none of the comparisons showed a statistically significant difference ( Table 2) . The 2-level patients were similar to the 1-level patients except that they were approximately 6 years older on average. Table 2 also shows the distributions of patients with radiculopathy and myelopathy. The distributions are further separated into patients with disc herniations and spondylosis. In several 1-level radiculopathy patients, both disc herniation and spondylosis were noted. A majority of the patients had radiculopathy. Approximately twice as many 1-level patients had disc herniations as compared with spondylosis. All 2-level patients presented with spondylosis.
Surgery Data
The mean operative time for the 1-level patients in the Phase I study was approximately 30 minutes longer than the operative time for the Phase II patients (Table 3) , a statistically significant difference (p < 0.001). Hospital stay was also significantly shorter for Phase II patients (p = 0.011). A similar trend was noted for blood loss, but it was not statistically significant. As expected, 2-level patients had longer operative times and more blood loss than 1-level patients. The predominant treatment level was C6-7 for 1-level patients and C5-6/C6-7 for 2-level patients.
Clinical Outcomes
The mean SF-36 PCS and MCS results are presented in Fig. 1 . The graph shows that the mean postoperative values for both the PCS and MCS were higher (better) than the preoperative values. Also, the mean PCS and MCS scores remained fairly constant across the postoperative intervals. Table 4 presents the PCS and MCS results as a function of the patients' underlying pathology (radiculopathy or myelopathy). The results are fairly similar for both pathology categories over time. However, the number of patients with myelopathy is small (8 patients). Patients with radiculopathy tended to show slightly higher PCS improvement as compared with myelopathy patients. The MCS improvements were mixed.
The NDI questionnaire was administered in the Phase II study. In addition, extended follow-up patients from the Phase I study also were asked to complete the form. For the Phase II study, all mean postoperative NDI scores were lower (better) than the preoperative value of 40.6. The combined Phase I and Phase II mean NDI values at 4 and 6 years were 19.8 and 20.3, respectively. Even though results in the preoperative to 2-year range are not available for the Phase I study patients, the 4-and 6-year results show low mean values that are consistent with, if not lower than, the Phase II study values. The values in the 2-level patients are similar to those in the 1-level patients.
The neck and arm pain results showed similar trends to the NDI results. The mean preoperative neck and arm pain scores for the Phase II study were 5.5 and 5.8, respectively. The mean values for both neck and arm pain decreased or improved after surgery as compared with the preoperative scores. The combined Phase I and Phase II mean neck pain values at 4 and 6 years postoperatively (2.2 and 2.0, respectively) were lower than those at 1 and 2 years following surgery (2.9 and 2.9, respectively). Similarly for arm pain, the 4-and 6-year values were 2.4 and 2.3, respectively, compared with 3.2 and 3.2, respectively, at 1 and 2 years postoperatively. The values in the 2-level patients were even lower than the values in the 1-level patients at 4 and 6 years postoperatively.
For 1-level patients, the overall neurological success rate exceeded 83% at all postoperative time periods, except at 4 years postoperatively when the rate dropped to 72% (58 of 81 patients). Sensory success at 4 years appeared to drive the overall success rate lower. The overall success rate rebounded to more than 88% (47 of 53 patients) at 6 years following surgery. The neurological success rates of the 2-level patients were similar to the rates of the 1-level patients, again with a drop at 4 years (4 of 9 patients; 44%) that was related to the sensory success rate.
The Odom classifications for the long-term Phase I and the Phase II study patients, which used the same methodology, are shown in Table 5 . The Phase I Odom classification results through 2 years postoperatively are not presented due to different assessment criteria. This results in lower total 1-level and no 2-level patient observations at the earlier postoperative times. Approximately 80% or more of the patients involved in the Phase II and extended Phase I study follow-up had Odom classifications of "excellent" or "good" at the postoperative time periods. At 4 and 6 years postoperatively, the "excellent/ good" rates for all of the 1-level patients were 88.8 and 90.6%, respectively. For 2-level patients, the "excellent/ good" rates at 4 and 6 years following surgery were also high at approximately 89% or greater.
Radiographic Outcomes
Radiographic outcomes regarding angular motion are presented in Table 6 . The postoperative mean values for the combined 1-level patients were fairly constant across time, in a range of approximately 7-9°, and within 2° of the preoperative value. The mean values for 2-level patients were similar and, in some cases, lower than those for 1-level patients. The angular motion means for the caudad level tended to be lower than the values for the cephalad level.
The angular motion data were also examined according to whether the value at each interval met or exceeded 2°, which was considered a cut-off point for the existence of motion. Over 83% of the total 1-level patients met the criteria. The values at 4 and 6 years postoperatively were less than those at 2 years and earlier. Similar to the mean angular motion presentations above, the motion rates in 2-level patients were consistent with the rates for 1-level patients (Fig. 2) .
Adverse Events and Second Surgeries
Because the discussion of adverse events pertains to safety, any findings related to the 4 patients in the Phase I study who declined participation in the Phase II study will be included. These findings would have occurred during their participation in the Phase I study. Therefore, the total population is considered to be 102 patients (92 1-level patients and 10 2-level patients) for examining adverse events. The reporting of adverse events was extensive, as noted by the somewhat high number of recorded events. In summary, a total of 65 patients (61 1-level and 4 2-level patients) had at least 1 adverse event that was recorded during their course in the studies regardless of follow-up duration after surgery. These 65 patients experienced more than 112 different events (105 events in 1-level patients and 7 events in 2-level patients). More than 40% of these findings were related to symptoms involving the neck, shoulder, arm, elbow, wrist, and/or hand. There were 10 neurological adverse events such as hypoesthesia or paresthesia. Two patients had surgical events noted. One of these events pertained to the operation of the milling disc that is used to prepare the vertebral bodies for the placement of the prosthesis, resulting in minor device migration, and the other involved the loosening and extrusion of the drainage catheter, which resulted in a prevertebral hematoma that required surgical evacuation within a day of the study surgery. One patient experienced postoperative hoarseness and vocal cord paralysis following an adjacent-level surgical procedure to treat a herniated disc. This second procedure occurred approximately 15 months after the original study surgery. An additional Bryan device was implanted at the adjacent level. Ten patients had adverse events reported to be associated with other cervical levels; these events included disc herniations and reports of radiculopathy. Approximately 20% of the patients had reports of issues related to the low back, leg, hip, and/or knee. One patient underwent the excision of a soft-tissue tumor in the neck that was believed to be metastatic carcinoma of unknown origin.
The investigators and/or their staff determined that most of the adverse events were not related to the Bryan device. Only 6 patients experienced events that were believed to be related to the device, either possibly or definitely. These events included reports of minor device migration, device removal, hoarseness and vocal cord paralysis, as well as 3 cases involving pain or neurological symptoms. Approximately 60% of the reported adverse events occurred 2 years after the study surgery, and approximately 15% of these events were continuations of earlier reports. Because these later adverse events are considered part of the total, their nature is included in the discussion above.
Eight patients underwent further neck surgery to treat symptoms, in addition to the 2 mentioned above who underwent tumor excision and prevertebral hematoma evacuation. The Bryan prosthesis was removed from 1 patient because of progressive spinal cord compression at the index level due to recurrent posterior osteophyte formation. The removal occurred approximately 6 years after the original surgery and was followed by fusion across multiple cervical levels. One patient underwent a laminoforaminotomy at the originally treated level because of unresolved radiculopathy symptoms. This procedure occurred less than 1 year following the original surgery, and this patient preferred not to be involved in the extended follow-up study. This patient's symptoms began within 2 weeks after surgery and minor posterior device migration was detected approximately 4 months later. There was no clear association of the 2 events. It was reported to us later on that she had presented to another institution where the prosthesis was removed and an ACDF was performed.
Further information about this case is not available. Another patient underwent a foraminotomy at another institution 5.8 years postoperatively (a bilevel case). Neither of these 2 procedures showed any significant impact on the position or angular motion of the prosthesis. Because of ongoing signs and symptoms of myelopathy, another patient underwent a laminectomy at the index level at another institution. Further information about this case is not available, and as a consequence it is unknown whether this laminectomy had an impact on the position and angular motion of the prosthesis. Four patients underwent procedures involving other cervical levels. Three of these patients had a Bryan prosthesis inserted to treat symptoms, whereas 1 patient underwent a fusion procedure. Two of these surgeries occurred within the first 2 years postoperatively and the other 2 occurred after 4.5 years following the original surgical procedure.
Second surgeries at the originally treated level were examined further using Kaplan-Meier life table methods. The results of the analysis are presented in Fig. 3 . The percentage of patients who did not have a second surgery that met the criteria is high at extended patient follow-up times. The success rate was 93.9% at > 7 years following surgery.
Discussion
The favorable clinical outcomes that were noted at 1 and 2 years after cervical disc replacement surgery using the Bryan Cervical Disc Prosthesis appear to continue at the 4 and 6 year follow-ups, both in terms of safety and of subjective patient comfort. The neck-and arm-pain values were even better at 4 and 6 years postoperatively than at 1 and 2 years postoperatively. In comparison, in our own long-term follow-up study on 180 patients after ACDF (mean follow-up 100.6 months, range 5-15 years), a long-term decrease in Odom classification was noted in 64% of the cases. 6 The duration of follow-up in both studies is, of course, not fully comparable.
Except for the case involving minor device migration due to inadequate milling of one of the endplates, the immediate postoperative adverse events did not appear to be different from what may be expected after ACDFs. From a neurological viewpoint the success rate at 4 years was lower than that at 2 and 6 years postoperatively due to the fact that more patients reported sensory disturbances at 4 years. It has to be taken into account that these data concern all patients as 1 group, and thus is not a longitudinal follow-up of each individual patient over the years.
Ten patients needed reinterventions, of which 4 had to be performed specifically at the index level. Two of these reoperations were performed during the first 2 postoperative years, one for ongoing radiculopathy (laminoforaminotomy) and the other for ongoing myelopathy (laminectomy); this last operation was performed at another institution. However, neither patient participated in the extended follow-up study, but we were informed that the former case had her prosthesis removed later on at another institution. This brings us to a total of 6 late reinterventions (6.1%) in a series of 98 long-term cases that we were able to follow ourselves prospectively. Because the follow-up period in other studies that have been published are limited to 2 years or less, they do not provide information about late surgical reoperations. 13 One case needed a reintervention at the index level at 6 years postoperatively due to recurrent myelopathy. This special case will be analyzed in a separate case report publication. Four patients needed interventions at an adjacent level (4.1%). In comparison, in our own longterm follow-up study on 180 patients after ACDF, 11 cases needed a reintervention because of an adjacent-level problem (6.11%). 6 From a radiological viewpoint, the angular motion analysis results at 4 and 6 years postoperatively appeared to indicate a loss of motion in a number of cases, although more than 80% of the implanted artificial discs remained mobile over a long follow-up period. This result concerns all patients as a group. A longitudinal radiological followup study and an analysis of possible preoperative factors such as preexisting motion and severity of disc degeneration that might have an impact on long-term motion will have to be performed. This investigation will be conducted in a separate study, in which angular motion will be assessed using a specially developed picture-recognizing software. This additional study will also address the items of heterotopic ossification at the index level and the progression of adjacent-level degeneration.
Conclusions
The favorable clinical and angular motion outcomes of the Bryan Cervical Disc Prosthesis that were previously observed at 1-and 2-years' follow-up after cervical disc replacement appear to continue at 4-and 6-years' followup. Both this clinical study and future radiological studies reflect an intermediate analysis of an ongoing long-term follow-up study of up to 10 years postoperatively.
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